Hydroxychloroquine No Better at Treating Coronavirus Than Conventional Care, Study Suggests


The antimalarial drug hydroxychloroquine offers no additional benefit to coronavirus patients already being treated with current methods, including bed rest and antiviral drugs, say authors of a pilot study into the drug’s effectiveness for COVID-19.

The study, published in the Journal of Zhejiang University and first reported by Bloomberg, involved 30 patients diagnosed with COVID-19, who were randomly split into two groups. Both received five-days of conventional treatments, including bed rest, oxygen inhalation and antiviral drugs, but one group was also administered 400 milligrams of hydroxychloroquine—a derivative of chloroquine used in the treatment of malaria and arthritis.